Home Current News Teva stops testing its migraine drug as cluster headache treatment

Teva stops testing its migraine drug as cluster headache treatment

99

Teva stops testing its migraine drug as cluster headache treatmentThe drug, known generically as fremanezumab, competes with rival treatments from Eli Lilly & Co and Amgen Inc. Lilly in November received the U.S. Food and Drug Administration’s “breakthrough” status for its migraine drug Emgality in treating episodic cluster headaches. In a late-stage trial, three out of four patients treated with Lilly’s drug saw at least a 50 percent reduction in weekly cluster headaches. Teva’s decision could be positive for Lilly’s drug in differentiating it from its rivals, BMO Capital Markets analyst Alex Arfaei said.